CI Global Health Sciences Corporate Class

Series A CAD
As of July 21, 2023 CI Global Health Sciences Corporate Class Z (ISC 2924) (DSC 2925) (LL 2928) merged into (ISC 201) (DSC 701) (LL 1701)
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date July 1996
CAD Total net assets ($CAD)
As at 2024-01-31
$142.0 million
NAVPS
As at 2024-02-27
$55.7913
MER (%)
As at 2023-09-30
2.34
Management fee (%) 1.90
Asset class Sector Equity
Currency CAD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.9027

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

A ISC 201
DSC SO* 701
LL SO 1701
E 16005
EF 15005
F 224
I 886
O 18005
P 90024
*No new purchases directly into switch only funds.

Performance2 As at 2024-01-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
2.52% 2.52% 6.03% 5.60% 7.85% 0.53% 4.17% 3.22% 7.77%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.9027
2021-03-26 0.3135
2020-12-18 0.5081
2020-09-25 0.5058
2020-06-26 0.3780
Payable date Total
2020-03-20 0.9301
2019-12-13 0.5339
2019-09-27 0.5996
2019-06-21 0.5646
2019-03-22 0.9043

CI PREFERRED PRICING4

Investment amount Combined fee reduction
$100,000 - $500,000 0.03%
$500,000 - $1,000,000 0.06%
$1,000,000 - $2,500,000 0.12%
$2,500,000 - $5,000,000 0.20%
$5,000,000 and above 0.32%

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series A CAD
As of July 21, 2023 CI Global Health Sciences Corporate Class Z (ISC 2924) (DSC 2925) (LL 2928) merged into (ISC 201) (DSC 701) (LL 1701)
 
Portfolio allocations5 As at 2024-01-31
Asset allocation (%)
  • US Equity 76.70
  • International Equity 20.62
  • Cash and Equivalents 2.68
Sector allocation (%)
  • Healthcare 91.81
  • Exchange Traded Fund 4.42
  • Cash and Cash Equivalent 2.68
  • Consumer Services 1.09
Geographic allocation(%)
  • United States 79.24
  • Denmark 7.78
  • United Kingdom 7.26
  • Germany 2.95
  • Switzerland 1.64
  • Ireland 1.05
  • Canada 0.08
Top holdings
Sector (%)
1. Eli Lilly and Co Drugs 10.00%
2. Humana Inc Healthcare Services 9.29%
3. UnitedHealth Group Inc Healthcare Services 9.09%
4. Novo Nordisk A/S Cl B Drugs 7.78%
5. Merck & Co Inc Drugs 5.92%
6. AstraZeneca PLC Drugs 4.88%
7. Zoetis Inc Cl A Drugs 4.47%
8. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 4.42%
9. AbbVie Inc Drugs 3.89%
10. Stryker Corp Healthcare Equipment 3.47%
11. Boston Scientific Corp Healthcare Equipment 3.44%
12. Johnson & Johnson Drugs 3.07%
13. Siemens Healthineers AG Healthcare Equipment 2.95%
14. Intuitive Surgical Inc Healthcare Equipment 2.95%
15. Thermo Fisher Scientific Inc Healthcare Equipment 2.88%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.